Abstract
Methotrexate is widely administered with mercaptopurine, a prodrug requiring activation into thioguanine nucleotides (TGN) to exert antileukemic effects. In vitro, methotrexate enhances TGN formation, but in vivo, such enhancement has yet to be demonstrated. We investigated whether TGN concentrations were related to methotrexate concentrations in children with acute lymphoblastic leukemia who received a weekly intravenous methotrexate (40 mg/m2) dose combined with daily mercaptopurine (75 mg/m2). A total of 141 erythrocyte TGN concentrations were measured with erythrocyte methotrexate polyglutamates (MTX-PG) concentrations in 87 patients. Average TGN concentrations ranged from 137 to 958 pmol/8 × 108 cells (median 389), average total MTX-PG concentrations (MTX- PG1–7) from 0.60 to 97.7 pmol/109cells (median 29), and average long chain polyglutamate concentrations (MTX-PG5–7) from 0 to 8.35 pmol/109 cells (median 2.43). Higher TGN concentrations correlated with higher MTX-PG5–7 concentrations (P = 0.002). These data support the practice of administering methotrexate with mercaptopurine during continuation therapy of acute lymphoblastic leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Elion GB . The purine path to chemotherapy Science 1989 24: 441–447
McLeod H, Krynetski E, Relling MV, Evans WE . Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia Leukemia 2000 14: 567–572
Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM . Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia Lancet 1990 336: 225–229
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui C-H, Evans WE . Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus J Natl Cancer Inst 1999 91: 2001–2008
Giverhaug T, Loennechen T, Aarbakke J . The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX) Gen Pharmacol 1999 33: 341–346
Bökkerink JP, Bakker MA, Hulscher TW, De Abreu RR, Schretlen ED, van Laarhoven JP, De Bruyn CH . Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts Biochem Pharmacol 1986 35: 3549–3555
Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, Gilchrist GS, Hammond D, Poplack DG . The effect of methotrexate on the bioavailability of oral 6-mercaptopurine Clin Pharmacol Ther 1987 41: 384–387
Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE . Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia Blood 1999 93: 2817–2823
Lennard L . Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells J Chromatogr 1987 423: 169–178
Fabre G, Matherly LH, Favre R, Catalin J, Cano JP . In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells Cancer Res 1983 43: 4648–4652
Schrøder H, Fogh K . Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia Cancer Chemother Pharmacol 1988 21: 145–149
Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui C-H, Evans WE . Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate J Clin Invest 1996 97: 73–80
Fontenelle LJ, Henderson JF . An enzymatic basis for the inability of erythrocytes to synthesize purine ribonucleotides de novo Biochim Biophys Acta 1969 177: 175–176
Valentine WN, Kurschner KK . Studies on human erythrocyte nucleotide metabolism. I. Monisotopic methodologies Blood 1972 39: 666–673
Da Costa M, Iqbal MP . The transport and accumulation of methotrexate in human erythrocytes Cancer 1981 48: 2427–2432
Schrøder H . Methotrexate pharmacokinetics in age-fractionated erythrocytes Cancer Chemother Pharmacol 1986 18: 203–207
Lennard L, Lilleyman JS . Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia J Clin Oncol 1989 7: 1816–1823
Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA . Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint Children's Cancer Group and Pediatric Oncology branch study Blood 1998 92: 3569–3577
Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L . Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology J Clin Oncol 1995 13: 345–351
Schmiegelow K, Bruunshuus I . 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia Cancer Chemother Pharmacol 1990 26: 288–292
Vilmer E, Suciu S, Ferster A, Bertrand Y, Cavé H, Thyss A, Benoit Y, Dastugue N, Fournier M, Souillet G, Manel AM, Robert A, Nelken B, Millot F, Lutz P, Rialland X, Mechinaud F, Boutard P, Behar C, Chantraine JM, Plouvier E, Laureys G, Brock P, Uyttebroeck A, Margueritte G, Plantaz D, Norton L, Francotte N, Gyselinck J, Waterkeyn C, Solbu G, Philippe N, Otten J . Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group Leukemia 2000 14: 2257–2266
Acknowledgements
This work was supported by grants CA 36401, CA 78224 and CA21765 from the National Institutes of Health; by a Center of Excellence grant from the State of Tennessee; and by American Lebanese Syrian Associated Charities (ALSAC).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dervieux, T., Hancock, M., Evans, W. et al. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 16, 209–212 (2002). https://doi.org/10.1038/sj.leu.2402373
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402373
Keywords
This article is cited by
-
Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
Scientific Reports (2023)
-
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations
Leukemia (2022)
-
FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia
Scientific Reports (2020)
-
Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
Journal of Hematology & Oncology (2015)
-
Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate
Journal of Pharmacokinetics and Pharmacodynamics (2014)